Caffeine Citrate Therapy for Apnea of Prematurity
CAFFEINE IS A DRUG commonly used in the neonatal intensive care unit. Given its frequent use, providers need to be well informed of the drug, its indications, mechanism of action, and pharmacokinetics. Caffeine has an important history of skeptics and variable practice preference, ultimately leading to fairly new evidence supporting its pharmacologic attributes for treatment of apnea of prematurity (AOP). Caffeine is also used to stimulate preextubation respiratory drive in the nursery and following anesthesia. The purpose of this column is to review the history of methylxanthine therapy as a treatment for AOP, examine the benefits of caffeine citrate (Cafcit®) as the methylxanthine of choice, including the pharmacology and pharmacokinetics of the drug, and review the current evidence-based practice for the use of Cafcit® in the treatment of AOP.
Document Type: Research Article
Publication date: November 1, 2011
- Neonatal Network®, established in April 1981, is a peer-reviewed journal dedicated to assisting neonatal nurses and related health care professionals remain current in their fields. Neonatal Network® acts as a vehicle for the exchange of information by providing up-to-date, relevant articles in the areas of evidence-based clinical practice, research, and education.
Neonatal Network® is issued six times a year; January/February, March/April, May/June, July/August, September/October, and November/December. With a circulation of 10,000, Neonatal Network® goes to more than 1,000 recognized Level II and Level III neonatal intensive care units in the United States.
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Academy of Neonatal Nursing Membership Information
- Academy of Neonatal Nursing Free Access to Journal Contents Online
- Request a Sample Issue
- ingentaconnect is not responsible for the content or availability of external websites